Duration of Anti-PD-1 Therapy in Metastatic Melanoma | MicrobiomeTrials← Back to trialsNCT02821013
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2016-10-31Est. Completion: 2027-12-31
Enrollment target: 614 participants Locations- Mildura Base Public Hospital, Victoria, Mildura, Australia
- Coffs Habour Health Campus - NCCI, Coffs Harbour, New South Wales, Australia
- Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia
- Westmead Hospital, Westmead, New South Wales, Australia
- Sunshine Coast University Hospital, Birtinya, Queensland, Australia
- Cairns Hospital, Cairns, Queensland, Australia
- Gold Coast University Hospital, Southport, Queensland, Australia
- The Queen Elizabeth Hospital, Woodville, South A., Australia
- Monash Medical Centre, Clayton, Victoria, Australia
- Alfred Hospital, Melbourne, Victoria, Australia
- Royal Brisbane and Womens Hospital, Herston, Australia
- Cross Cancer Institute, Edmonton, Alberta, Canada
- BCCA - Surrey, Surrey, British Columbia, Canada
- BCCA - Vancouver, Vancouver, British Columbia, Canada
- BCCA - Victoria, Victoria, British Columbia, Canada
- Horizon Health Network, Fredericton, New Brunswick, Canada
- Royal Victoria Regional Health Centre, Barrie, Ontario, Canada
Other microbiome trials you might be interested in
Advanced Esophageal Squamous Cell CarcinomaAdvanced Renal Cell CarcinomaClinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage IIB Cutaneous Melanoma AJCC v8Clinical Stage IIC Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8Esophageal CarcinomaGastroesophageal Junction AdenocarcinomaHepatocellular CarcinomaLocally Advanced Urothelial Carcinoma
Health Sciences North, Greater Sudbury, Ontario, CanadaJuravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, CanadaKingston Health Sciences Centre, Kingston, Ontario, CanadaWaterloo Regional Health Network (WRHN), Kitchener, Ontario, CanadaLondon Health Sciences Centre Research Inc., London, Ontario, CanadaTrillium Health Partners - Credit Valley Hospital, Mississauga, Ontario, CanadaLakeridge Health Oshawa, Oshawa, Ontario, CanadaOttawa Hospital Research Institute, Ottawa, Ontario, CanadaOdette Cancer Centre, Toronto, Ontario, CanadaUniversity Health Network, Toronto, Ontario, CanadaThe Research Institute of the McGill University, Montreal, Quebec, CanadaAllan Blair Cancer Centre, Regina, Saskatchewan, CanadaSaskatoon Cancer Centre, Saskatoon, Saskatchewan, CanadaLung Non-Small Cell Carcinoma
Malignant Solid Neoplasm
Metastatic Colorectal Carcinoma
Metastatic Cutaneous Melanoma
Metastatic Esophageal Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Urothelial Carcinoma
Recurrent Esophageal Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Stage IV Renal Cell Cancer AJCC v8
Unresectable Cutaneous Melanoma
Unresectable Esophageal Squamous Cell Carcinoma
Urothelial Carcinoma
Unresectable Urothelial Carcinoma
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setti…
Jacksonville, United StatesEst. completion Dec 31, 2026
Unresectable Cutaneous Melanoma
This first-in-human study will evaluate the safety, clinical activity, and immunologic effects of combining axelopran wi…
Pittsburgh, United StatesEst. completion Jul 31, 2028